{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T03:46:00Z","timestamp":1785901560823,"version":"3.56.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Netherlands Organization for Scientific Research"},{"name":"Veni","award":["016.176.024"],"award-info":[{"award-number":["016.176.024"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,3,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pulmonary infections caused by non-tuberculous mycobacteria (NTM) are hard to treat and have low cure rates despite intensive multidrug therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To assess the feasibility of tedizolid, a new oxazolidinone, for the treatment of Mycobacterium avium and Mycobacterium abscessus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We determined MICs of tedizolid for 113 isolates of NTM. Synergy with key antimycobacterial drugs was assessed using the chequerboard method and calculation of the FIC index (FICI). We performed time\u2013kill kinetics assays of tedizolid alone and combined with amikacin for M. abscessus and with ethambutol for M. avium. Human macrophages were infected with M. abscessus and M. avium and subsequently treated with tedizolid; intracellular and extracellular cfu were quantified over time.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>NTM isolates generally had a lower MIC of tedizolid than of linezolid. FICIs were lowest between tedizolid and amikacin for M. abscessus (FICI\u2009=\u20090.75) and between tedizolid and ethambutol for M. avium (FICI\u2009=\u20090.72). Clarithromycin and tedizolid showed initial synergy, which was abrogated by erm(41)-induced macrolide resistance (FICI\u2009=\u20090.53). Tedizolid had a weak bacteriostatic effect on M. abscessus and combination with amikacin slightly prolonged its effect. Tedizolid had concentration-dependent activity against M. avium and its efficacy was enhanced by ethambutol. Both combinations had a concentration-dependent synergistic effect. Tedizolid could inhibit the intracellular bacterial population of both M. avium and M. abscessus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Tedizolid should be further investigated in pharmacodynamic studies and clinical trials for M. avium complex pulmonary disease. It is less active against M. abscessus, but still promising.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz511","type":"journal-article","created":{"date-parts":[[2019,11,15]],"date-time":"2019-11-15T07:09:56Z","timestamp":1573801796000},"page":"609-617","source":"Crossref","is-referenced-by-count":43,"title":["Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?"],"prefix":"10.1093","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0281-4895","authenticated-orcid":false,"given":"Mike Marvin","family":"Ruth","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A C M","family":"Koeken","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lian J","family":"Pennings","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin M","family":"Svensson","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Pharmacy, Radboud University Medical Center, Nijmegen, The Netherlands"},{"name":"Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heiman F L","family":"Wertheim","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Hoefsloot","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0581-2003","authenticated-orcid":false,"given":"Jakko","family":"van Ingen","sequence":"first","affiliation":[{"name":"Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"2020021411000286700_dkz511-B1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"2020021411000286700_dkz511-B2","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1183\/09031936.00149212","article-title":"The geographic diversity of nontuberculous mycobacteria isolated from pulmonary samples: an NTM-NET collaborative study","volume":"42","author":"Hoefsloot","year":"2013","journal-title":"Eur Respir J"},{"key":"2020021411000286700_dkz511-B3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ijid.2016.03.006","article-title":"Update on pulmonary disease due to non-tuberculous mycobacteria","volume":"45","author":"Stout","year":"2016","journal-title":"Int J Infect Dis"},{"key":"2020021411000286700_dkz511-B4","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"2020021411000286700_dkz511-B5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1586\/14787210.2013.830413","article-title":"Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence","volume":"11","author":"van Ingen","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2020021411000286700_dkz511-B6","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1055\/s-0033-1333575","article-title":"Management of nontuberculous mycobacterial (NTM) lung disease","volume":"34","author":"Philley","year":"2013","journal-title":"Semin Respir Crit Care Med"},{"key":"2020021411000286700_dkz511-B7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1183\/09031936.00169114","article-title":"The tolerability of linezolid in the treatment of nontuberculous mycobacterial disease","volume":"45","author":"Winthrop","year":"2015","journal-title":"Eur Respir J"},{"key":"2020021411000286700_dkz511-B8","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J Clin Microbiol"},{"key":"2020021411000286700_dkz511-B9","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1093\/cid\/civ501","article-title":"Tedizolid: the first once-daily oxazolidinone class antibiotic","volume":"61","author":"Burdette","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2020021411000286700_dkz511-B10","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1128\/AAC.46.5.1475-1480.2002","article-title":"Intrapulmonary pharmacokinetics of linezolid","volume":"46","author":"Conte","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021411000286700_dkz511-B11","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021411000286700_dkz511-B12","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1093\/jac\/dkw484","article-title":"Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity","volume":"72","author":"Yuste","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020021411000286700_dkz511-B13","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1093\/jac\/dkx305","article-title":"Tedizolid is highly bactericidal in the treatment of pulmonary Mycobacterium avium complex disease","volume":"72 Suppl 2","author":"Deshpande","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020021411000286700_dkz511-B14","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diagmicrobio.2017.11.001","article-title":"In vitro activity of tedizolid against the Mycobacterium abscessus complex","volume":"90","author":"Compain","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2020021411000286700_dkz511-B15","doi-asserted-by":"crossref","first-page":"e01915-18","DOI":"10.1128\/AAC.01915-18","article-title":"In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against Mycobacterium abscessus","volume":"63","author":"Le Run","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021411000286700_dkz511-B16","year":"2011"},{"key":"2020021411000286700_dkz511-B17","doi-asserted-by":"crossref","first-page":"e01208-18","DOI":"10.1128\/AAC.01208-18","article-title":"Minocycline has no clear role in the treatment of Mycobacterium abscessus disease","volume":"62","author":"Ruth","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2020021411000286700_dkz511-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2020021411000286700_dkz511-B19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020021411000286700_dkz511-B20","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1007\/s11095-015-1632-3","article-title":"Pharmacodynamic and response surface analysis of linezolid or vancomycin combined with meropenem against Staphylococcus aureus","volume":"32","author":"Wicha","year":"2015","journal-title":"Pharm Res"},{"key":"2020021411000286700_dkz511-B21","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1093\/jac\/dkz143","article-title":"Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics\/pharmacodynamics and Bayesian framework mathematical models","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2020021411000286700_dkz511-B22","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1080\/14656566.2018.1519021","article-title":"An evaluation of tedizolid for the treatment of MRSA infections","volume":"19","author":"Hall","year":"2018","journal-title":"Expert Opin Pharmacother"},{"key":"2020021411000286700_dkz511-B23","doi-asserted-by":"crossref","first-page":"ii48","DOI":"10.1093\/jac\/dkx307","article-title":"A novel ceftazidime\/avibactam, rifabutin, tedizolid and moxifloxacin (CARTM) regimen for pulmonary Mycobacterium avium disease","volume":"72 Suppl 2","author":"Deshpande","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2020021411000286700_dkz511-B24","doi-asserted-by":"crossref","first-page":"E137.","DOI":"10.3390\/antibiotics8030137","article-title":"Tedizolid versus linezolid for the treatment of acute bacterial skin and skin structure infection: a systematic review and meta-analysis","volume":"8","author":"Lan","year":"2019","journal-title":"Antibiotics (Basel)"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/3\/609\/32470103\/dkz511.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/75\/3\/609\/32470103\/dkz511.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T11:01:40Z","timestamp":1581678100000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/75\/3\/609\/5690335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":24,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,12,30]]},"published-print":{"date-parts":[[2020,3,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz511","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,3]]},"published":{"date-parts":[[2019,12,30]]}}}